Samsung E&A (Seoul, South Korea) has won a contract for the main construction of the Songdo Bio Raw Materials Plant from global life science company Sartorius AG (Göttingen, Germany).
On 21 March, Samsung E&A signed a KRW 518.62 billion contract with Sartorius Korea Operations LLC for the ‘Sartorius Songdo Campus’ in Korea. The contract signing ceremony held at E&A’s Global Engineering Center (GEC) in Sangil-dong, Gangdong-gu, Seoul, was attended by top executives from both companies, including Hong Namkoong, President and CEO of SAMSUNG E&A, and Doug Sang Kim, Managing director of Sartorius Korea Operations.
The plant will be built in the Incheon Free Economic Zone in Songdo, Incheon, serving as a production and research facility for raw materials used in biopharmaceuticals. It will manufacture sterile bags, membrane filters, and cell culture media, and also provide Non-clinical CRO(Contract Research Organization) services.
Based on its prior design work, Samsung E&A will independently handle equipment procurement and construction and target completion for 2027.
Samsung E&A and its technology-driven ‘FEED to EPC Strategy‘, were involved in this project from the early stages, including conceptual and basic design. It has now secured the main construction contract, allowing it to participate in the entire project lifecycle. Furthermore, through this contract with Sartorius, a global leading supplier in biopharmaceutical materials and components, Samsung E&A has secured a new global bio customer and expanded its business area from biopharmaceutical plants to biomaterial plants, laying the foundation for continued growth through linked orders.
Hong Namkoong, President and CEO of Samsung E&A stated: “We will successfully carry out the project with our abundant execution experience, differentiated innovation, and technological prowess, and further strengthen our position in the bio plant market.”